FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses

Skeletal Radiology

Volumn 32, Issue 3, 2003, Pages 133-138

  Aoki, Jun ^a   Watanabe, H ^a   Shinozaki, T ^a   Takagishi, K ^a   Tokunaga, M ^a,b   Koyama, Y ^a   Sato, N ^a   Endo, K ^a  

^a GUNMA UNIVERSITY   (Japan)

^b Ohta General Hospital   (Japan)

Author keywords

Emission CT(ECT); Fluorine; Glucose; Soft tissues, diseases; Soft tissues, neoplasms; Soft tissues, radionuclide studies

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BENIGN TUMOR; CALCULATION; CONTROLLED STUDY; DESMOID TUMOR; DIFFERENTIAL DIAGNOSIS; DRUG ACCUMULATION; DRUG UPTAKE; FEMALE; GIANT CELL TUMOR; HISTOPATHOLOGY; HUMAN; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NEURILEMOMA; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SARCOIDOSIS; SCHOOL CHILD; SOFT TISSUE TUMOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYNOVIAL SARCOMA; TENDON SHEATH; COMPUTER ASSISTED EMISSION TOMOGRAPHY; MIDDLE AGED; SCINTISCANNING;

DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; SOFT TISSUE NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0037711096     PISSN: 03642348     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00256-002-0586-9     Document Type: Article

References (27)

1. Sundaram M, McGuire MH, Herbold DR. Magnetic resonance imaging of soft tissue masses. An evaluation of fifty-three histologically proven tumors. Magn Reson Imaging 1988; 6:237-248.
2. Kransdorf MJ, Murphey MD. Imaging of soft tissue tumors. In: Kransdorf MJ, Murphey MD, eds. Imaging of soft tissue tumors. Philadelphia: Saunders, 1997:37-56.
3. Hoh CK, Schiepers C, Seltzer MA, et al. PET in oncology: will it replace the other modalities? Semin Nucl Med 1997; 27:94-106.
4. Brock CS, Meikle SR, Price P. Dose fluorine-18 fluorodeoxyglucose metabolic imaging of tumors benefit oncology? Eur J Nucl Med 1997; 24:691-705.
5. Bar-Shalon R, Valdivia AY, Blaufox MD. PET imaging in oncology. Semin Nucl Med 2000; 30:150-185.
6. Kern KA, Brunetti A, Norton JA, et al. Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med 1988; 29:181-186.
7. Griffeth LK, Dehdashti FD, McGire AH, et al. PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-d-glucose. Radiology 1992; 182:185-194.
8. Adler LP, Blair HF, Makley JT, et al. Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 1991; 32:1508-1512.
9. Nieweg OE, Pruim J, van Ginkel RJ, et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 1996; 37:257-261.
10. Schwarzbach MHM, Dimitrakopoulou-Strauss A, Willeke F, et al. Clinical value of [18-F]fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann Surg 1999; 231: 380-386.
11. Lucas JD, O'Doherty MJ, Cronin BF, et al. Prospective evaluation of soft tissue masses and sarcomas using fluoro-deoxyglucose positron emission tomography. Br J Surg 1999; 86:550-556.
12. Hamacher K, Coenen HH, Stocklin G. Efficient stereospecific synthesis of non-carrier-added 2-[18F]-fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986; 27:235-238.
13. Meikle SR, Bailey DL, Hooper PK, et al. Simultaneous emission and transmission measurement for attenuation correction in whole-body PET. J Nucl Med 1995; 36:1680-1688.
14. Inoue T, Kim EE, Komaki R, et al. Detecting recurrent or residual lung cancer with PET-FDG. J Nucl Med 1995; 36:788-793.
15. Watanabe H, Shinozaki T, Yanagawa T, et al. Glucose metabolic analysis of musculoskeletal tumors using 18fluorine-FDG PET as an aid to preoperative planning. J Bone Joint Surg Br 2000; 82:760-767.
16. Watanabe H, Inoue T, Shinozaki T, et al. PET imaging of musculoskeletal tumors with fluorine-18 alpha-methyltyrosine: comparison with fluorine-18 flurodeoxyglucose PET. Eur J Nucl Med 2000; 27:1509-1517.
17. Lodge MA, Lucus JD, Marsden PK, Cronin BF, O'Doherty MJ, Smith MA. A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med 1999; 26:22-30.
18. Dimitrakopoulou-Strauss A, Strauss LG, Schwarzbach M, et al. Dynamic PET18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading. J Nucl Med 2001; 42:713-720.
19. Meszaros K, Lang CH, Bagby GJ, Spitzer JJ. Contribution of different organs to increased glucose consumption after endotoxin administration. J Biol Chem 1987; 262:10965-10970.
20. Gamelli RL, Liu H, He L, Hofmann CA. Augmentation of glucose transporter-1 in macrophages following thermal injury and sepsis in mice. J Leukoc Biol 1996; 59:639-647.
21. Palmer WE, Rosenthal DI, Schoenberg OI, et al. Quantification of inflammation in the wrist with gadolinium-enhanced MR imaging and PET with 2-[F-18]-fluoro-2-deoxy-d-glucose. Radiology 1995; 196:647-655.
22. Guhlmann A, Brechy-Krauss D, Suger G, et al. Chronic osteomyelitis: detection with FDG PET and correlation with histopathologic findings. Radiology 1998; 206:749-754.
23. Brudin LH, Valid S-O, Rhodes CG, et al. Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med 1994; 21:297-305.
24. Yamada Y, Uchida Y, Tatsumi K, et al. Fluorine-18-fluorodeoxyglucose and carbon-11-methionine evaluation of lymphadenopathy in sarcoidosis. J Nucl Med 1998; 39:1160-1166.
25. Aoki J, Watanabe H, Shinozaki T, et al. FDG-PET of primary benign and malignant bone tumors: standardized up-take value in 52 lesions. Radiology 2001; 219;774-777.
26. Kubota K, Kubota R, Yamada S. FDG accumulation in tumor tissue (editorial). J Nucl Med 1993; 34:419-421.
27. Magnani P, Cherian PV, Gould GW, Greene DA, Sima AAF, Brosius FC. Glucose transporters in rat peripheral nerve: paranodal expression of GLUT1 and GLUT3. Metabolism 1996; 45:1466-1473.